Thomas Equels, CEO of Hemispherx, attended the conference and commented on Dr. Kalinski's presentation. "We are deeply grateful for the pioneering work done at University of Pittsburgh Cancer Institute and Roswell Park Cancer Institute which supports this breakthrough research indicating an important potential future role for Ampligen (rintatolimod) as a superior TLR immune system amplifier in oncology combination therapies. Because of our company's pioneering work in both AIDS/HIV and ME/CFS we have approximately 100,000 doses of Ampligen administered IV in humans. No other TLR agonist has such a 'ready-made' safety profile with the potential to facilitate rapid deployment in oncology."A bout Hemispherx Biopharma Hemispherx Biopharma, Inc., is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials. Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/462f0df7-b2d4-4a77-8152-b3b84da81b26.
ContactHemispherx Biopharma Phone Number: 800-778-4042 Email: IR@hemispherx.net